MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

Natera Inc

Slēgts

SektorsVeselības aprūpe

158.72 -1.71

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

158.36

Max

161.48

Galvenie mērījumi

By Trading Economics

Ienākumi

-13M

-67M

Pārdošana

26M

502M

EPS

-0.5

Peļņas marža

-13.338

Darbinieki

4,424

EBITDA

-33M

-79M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+27.6% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.8B

23B

Iepriekšējā atvēršanas cena

160.43

Iepriekšējā slēgšanas cena

158.72

Ziņu noskaņojums

By Acuity

14%

86%

17 / 375 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Natera Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 7. jūl. 15:29 UTC

Galvenie tirgus virzītāji

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

2025. g. 7. jūl. 23:44 UTC

Tirgus saruna

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

2025. g. 7. jūl. 23:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. jūl. 23:41 UTC

Tirgus saruna

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

2025. g. 7. jūl. 23:19 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 7. jūl. 23:19 UTC

Tirgus saruna

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

2025. g. 7. jūl. 22:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 7. jūl. 22:20 UTC

Tirgus saruna

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

2025. g. 7. jūl. 21:34 UTC

Iegādes, apvienošanās, pārņemšana

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

2025. g. 7. jūl. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 7. jūl. 20:45 UTC

Iegādes, apvienošanās, pārņemšana

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

2025. g. 7. jūl. 20:16 UTC

Tirgus saruna

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

2025. g. 7. jūl. 19:37 UTC

Tirgus saruna

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

2025. g. 7. jūl. 19:12 UTC

Tirgus saruna

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

2025. g. 7. jūl. 18:33 UTC

Tirgus saruna

Gold Flat as Investors Assess Market Direction -- Market Talk

2025. g. 7. jūl. 18:27 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. jūl. 16:53 UTC

Peļņas

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

2025. g. 7. jūl. 16:30 UTC

Tirgus saruna

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

2025. g. 7. jūl. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 7. jūl. 16:05 UTC

Iegādes, apvienošanās, pārņemšana

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

2025. g. 7. jūl. 15:41 UTC

Tirgus saruna

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

2025. g. 7. jūl. 15:41 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 7. jūl. 15:40 UTC

Tirgus saruna

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

2025. g. 7. jūl. 15:30 UTC

Tirgus saruna

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

2025. g. 7. jūl. 15:18 UTC

Tirgus saruna

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

2025. g. 7. jūl. 15:14 UTC

Iegādes, apvienošanās, pārņemšana

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

2025. g. 7. jūl. 15:00 UTC

Iegādes, apvienošanās, pārņemšana

GSK Completes Acquisition of Efimosfermin

2025. g. 7. jūl. 14:52 UTC

Tirgus saruna

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

2025. g. 7. jūl. 14:51 UTC

Tirgus saruna

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

2025. g. 7. jūl. 14:45 UTC

Tirgus saruna

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Salīdzinājums

Cenas izmaiņa

Natera Inc Prognoze

Cenas mērķis

By TipRanks

27.6% augšup

Prognoze 12 mēnešiem

Vidējais 206.4 USD  27.6%

Augstākais 251 USD

Zemākais 185 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Natera Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

11 ratings

11

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

153.79 / N/AAtbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

17 / 375 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.